These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Converting enzyme, angiotensin II and hypertensive disease. Soffer RL; Case DB Am J Med; 1978 Jan; 64(1):147-160. PubMed ID: 203191 [No Abstract] [Full Text] [Related]
5. The use of saralasin to evaluate the function of the brain renin-angiotensin system. Reid IA Prog Biochem Pharmacol; 1976; 12():117-34. PubMed ID: 1019160 [TBL] [Abstract][Full Text] [Related]
6. Clinical implications of renin in the hypertensive patient. Brunner HR; Gavras H JAMA; 1975 Sep; 233(10):1091-3. PubMed ID: 1174160 [No Abstract] [Full Text] [Related]
7. Comparison between saralsin and converting enzyme inhibitor in hypertensive disease. Case DB; Wallace JM; Laragh JH Kidney Int Suppl; 1979 Mar; (9):S107-114. PubMed ID: 225598 [No Abstract] [Full Text] [Related]
8. Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man. Pettinger WA; Mitchell HC N Engl J Med; 1975 Jun; 292(23):1214-7. PubMed ID: 236513 [TBL] [Abstract][Full Text] [Related]
10. Blockade of renin or angiotensin for understanding human hypertension: a comparison of propranolol, saralasin and converting enzyme blockade. Laragh JH; Case DB; Wallace JM; Keim H Fed Proc; 1977 Apr; 36(5):1781-7. PubMed ID: 191300 [TBL] [Abstract][Full Text] [Related]
11. Intrarenal effects of the renin-angiotensin system. Ploth DW; Navar LG Fed Proc; 1979 Aug; 38(9):2280-5. PubMed ID: 456614 [No Abstract] [Full Text] [Related]
12. Mechanism of blood pressure reduction by teprotide (SQ 20881) in rats. Jaeger P; Ferguson RK; Brunner HR; Kirchertz EJ; Gavras H Kidney Int; 1978 Apr; 13(4):289-96. PubMed ID: 651128 [TBL] [Abstract][Full Text] [Related]
13. Interactions between angiotensin II, sympathetic nerve-mediated pressor response and cyclo-oxygenase products in the pithed rat. Grant TL; McGrath JC Br J Pharmacol; 1988 Dec; 95(4):1220-8. PubMed ID: 3146400 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor. Morton JJ; Casals-Stenzel J; Lever AF; Millar JA; Riegger AJ; Tree M Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):233S-241S. PubMed ID: 223615 [TBL] [Abstract][Full Text] [Related]
15. Participation of renal, but not of submaxillary renin in the homeostasis of the blood pressure after experimentally induced hypotension in mice. Bing J; Poulsen K Acta Pathol Microbiol Scand A; 1976 Sep; 84(5):391-6. PubMed ID: 970127 [TBL] [Abstract][Full Text] [Related]
16. [Various inhbitors of the renin-angiotensin system and their clinical use]. Bar-Andziak E Pol Arch Med Wewn; 1979 Jan; 61(1):69-74. PubMed ID: 370806 [No Abstract] [Full Text] [Related]
18. Effect of 12-hour infusions of saralasin or captopril on blood pressure in hypertensive conscious rats. Relationship to plasma renin, duration of hypertension, and effect of unclipping. Bing RF; Russell GI; Swales JD; Thurston H J Lab Clin Med; 1981 Aug; 98(2):302-10. PubMed ID: 7019368 [TBL] [Abstract][Full Text] [Related]
20. The second Volhard Lecture: The use of blocking agents to define the functions of the renin--angiotensin system. Davis JO Clin Sci Mol Med Suppl; 1975 Jun; 2():3s-14s. PubMed ID: 802643 [No Abstract] [Full Text] [Related] [Next] [New Search]